Boehringer Ingelheim

MD Anderson and Boehringer Ingelheim to Partner on Cancer, Found a Virtual R&D Center
MD Anderson and Boehringer Ingelheim to Partner on Cancer, Found a Virtual R&D Center
BioSpace
Boehringer Ingelheim
MD Anderson Cancer Center
cancer
R&D
Flag link:
Boehringer posts solid first half as business revamp beds in
Boehringer posts solid first half as business revamp beds in
PM Live
Boehringer Ingelheim
earnings
Spiriva
Jardiance
Flag link:
Looking for Ofev follow-up, Boehringer picks up Bridge Biotherapeutics' IPF med for $50M
Looking for Ofev follow-up, Boehringer picks up Bridge Biotherapeutics' IPF med for $50M
Fierce Biotech
Boehringer Ingelheim
Bridge Biotherapeutics
Ofeva
IPF
BBT-877
Flag link:
Boehringer buys up cancer vaccine player, eyes oncology combo strategy
Boehringer buys up cancer vaccine player, eyes oncology combo strategy
Fierce Biotech
Boehringer Ingelheim
M&A
Amal Therapeutics
Flag link:
Boehringer races to catch up in NASH through Yuhan deal
Boehringer races to catch up in NASH through Yuhan deal
BioCentury
Boehringer Ingelheim
NASH
Yuhan
Flag link:
FDA fast-tracks BI, Lilly's Jardiance in chronic heart failure
FDA fast-tracks BI, Lilly's Jardiance in chronic heart failure
Fierce Pharma
Eli Lilly
Boehringer Ingelheim
Jardiance
chronic heart failure
fast track
Flag link:
Boehringer leads investment in digital therapy for myopia
Boehringer leads investment in digital therapy for myopia
Pharmaforum
Dopavision
Boehringer Ingelheim
myopia
digital medicine
digital therapy
Flag link:
Boehringer, OSE doses first patient in phase 1 trial of SIRPα antagonist monoclonal antibody
Boehringer, OSE doses first patient in phase 1 trial of SIRPα antagonist monoclonal antibody
Pharmaceutical Business Review
Boehringer Ingelheim
OSE Immuotherapeutics
clinical trials
BI 765063
solid tumors
Flag link:
Boehringer Ingelheim opens inhaler plant with 200 jobs
Boehringer Ingelheim opens inhaler plant with 200 jobs
Fierce Pharma
Boehringer Ingelheim
inhalers
drug manufacturing
Spain
Flag link:
ADA: Lilly, Boehringer's DPP-4 drug Tradjenta ties generic rival in heart safety study
ADA: Lilly, Boehringer's DPP-4 drug Tradjenta ties generic rival in heart safety study
Fierce Pharma
Eli Lilly
Boehringer Ingelheim
ADA
diabetes
Tradjenta
Flag link:
Boehringer Ingelheim, Gubra to develop anti-obesity peptide poly-agonists
Boehringer Ingelheim, Gubra to develop anti-obesity peptide poly-agonists
Pharmaceutical Business Review
obesity
peptide poly-agonists
Boehringer Ingelheim
Gubra
Flag link:
Boehringer looks to enhance COPD care with new registry
Boehringer looks to enhance COPD care with new registry
Pharmaforum
Boehringer Ingelheim
COPD
patients
patient registry
Flag link:
AbbVie stock up 1.3% after announcing resolution to litigation over Humira in the U.S.
AbbVie stock up 1.3% after announcing resolution to litigation over Humira in the U.S.
Marketwatch
AbbVie
biosimilars
Humira
patents
Boehringer Ingelheim
Flag link:
Researchers warn about gangrene cases in patients on SGLT2 diabetes drugs
Researchers warn about gangrene cases in patients on SGLT2 diabetes drugs
Fierce Pharma
gangrene
diabetes
JNJ
Invokana
AstraZeneca
Farxiga
Eli Lilly
Boehringer Ingelheim
Jardiance
Flag link:
BI and Lilly's diabetes drug Jardiance reverses heart failure in animal models
BI and Lilly's diabetes drug Jardiance reverses heart failure in animal models
Fierce Biotech
Eli Lilly
Boehringer Ingelheim
Jardiance
type 2 diabetes
heart failure
Flag link:
BI chief “regrets” Brexit, but continues to invest in UK
BI chief “regrets” Brexit, but continues to invest in UK
Pharmaforum
UK
Brexit
Boehringer Ingelheim
Flag link:
PureTech, Boehringer partner to develop lymph node-targeting cancer immunotherapies
PureTech, Boehringer partner to develop lymph node-targeting cancer immunotherapies
BioCentury
Boehringer Ingelheim
PureTech
lymphatic targeting
GI cancers
Flag link:
Boehringer’s blockbuster Spiriva under pressure, profits down
Boehringer’s blockbuster Spiriva under pressure, profits down
Pharmaforum
Boehringer Ingelheim
earnings
Spiriva
Flag link:
Boehringer Ingelheim buys MacroDel platform developer ICD Therapeutics
Boehringer Ingelheim buys MacroDel platform developer ICD Therapeutics
Pharmaceutical Business Review
Boehringer Ingelheim
MacroDel biologics
M&A
ICD Therapeutics
Flag link:
Hand over your Humira biosim launch plans; judge tells Boehringer in AbbVie patent fight
Hand over your Humira biosim launch plans; judge tells Boehringer in AbbVie patent fight
Fierce Pharma
AbbVie
Boehringer Ingelheim
Humira
biosimilars
Flag link:

Pages